Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
Two decades of SPECT/CT–the coming of age of a technology: an updated review of literature evidence
O Israel, O Pellet, L Biassoni, D De Palma… - European journal of …, 2019 - Springer
Purpose Single-photon emission computed tomography (SPECT) combined with computed
tomography (CT) was introduced as a hybrid SPECT/CT imaging modality two decades ago …
tomography (CT) was introduced as a hybrid SPECT/CT imaging modality two decades ago …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Apalutamide treatment and metastasis-free survival in prostate cancer
Background Apalutamide, a competitive inhibitor of the androgen receptor, is under
development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide …
development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide …
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer
Purpose: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation
therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant …
therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant …
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2023 - Springer
Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact …
Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after
radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga …
radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga …
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography
(PET)/computed tomography (CT) is used for (re) staging prostate cancer (PCa) and as a …
(PET)/computed tomography (CT) is used for (re) staging prostate cancer (PCa) and as a …
Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy
M Sathekge, F Bruchertseifer, M Vorster… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …
making this antigen a suitable target for radioligand therapy of the disease. Here we report …
Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot …
The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)–targeted
PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl) …
PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl) …